Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trulicity in Type 2 Diabetes Mellitus
NCT00804986Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2008
- Primary completion
- Jan 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 11
01
Overview
A Phase 2 trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Dec 2008; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00804986.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00804986.